Notes on pH, ionization, and absorption in pharmacokinetics

Pharmacokinetics: pH, Ionization, Absorption, and First-Pass Effects

• Big picture: Getting a drug from the outside world into the bloodstream, across membranes into the target tissue, and then out of the body involves multiple steps and is highly pH-dependent. Absorption, distribution, metabolism, and excretion are all influenced by whether the drug is charged or neutral at the pH of each compartment (stomach, gut, blood, urine, tissues).

• Key concept: Ionization state changes with pH. Many drugs are weak acids or weak bases, so they gain or lose protons as pH changes along the GI tract and in body compartments. This protonation state affects membrane crossing and thus absorption and distribution.

• Central tool: Henderson–Hasselbalch framework. We will use the equation to predict how much of a drug is protonated (charged) versus unprotonated (neutral) at a given pH and pKa.

• Henderson–Hasselbalch relationship used in this course (focus on protonated/unprotonated for crossing membranes):
  \log \left(\frac{[\text{protonated}]}{[\text{unprotonated}]}\right) = \mathrm{p}Ka - \mathrm{pH}. This can be rearranged to predict the ratio as a function of pH and pKa: \frac{[\text{protonated}]}{[\text{unprotonated}]} = 10^{\mathrm{p}Ka - \mathrm{pH}}.
  The protonated form is the charged form for acids; the unprotonated form is neutral. For bases, the roles are reversed.

• Important implication: Crossing membranes depends on the drug being neutral (lipophilic). Charged species cross poorly because membranes are lipid-rich. Therefore, whether the drug is absorbed or not is dictated by its charge state at the local pH.

• Physiological pH range encountered by drugs:

  • Stomach: ~pH 1–2 (very acidic)
  • Small intestine: ~pH 6–7.5 (neutral to basic relative to the stomach)
  • Blood: ~pH 7.35–7.45 (~7.4)
  • Urine: ~pH 4.5–8 (can vary widely)
  • The liver and other tissues have their own pH environments but are generally around neutral to slightly basic.
  • Note: The slide notes emphasize a dramatic pH sweep across the GI tract and compartments, which drives transient ionization states.

• Concept of ion trapping:

  • If a drug crosses a membrane in one compartment when it is in the neutral form, but then encounters a different pH in the next compartment that protonates or deprotonates it, the drug may become charged and unable to cross back. This can trap the drug in that compartment (ion trapping).
  • Example idea: a weak acid drug can be trapped in a more basic compartment if it becomes deprotonated (charged) after crossing into that compartment.
  • Saliva ion trapping has been observed and used for detection in some contexts.
  • In the kidney, altering urine pH can change the charged fraction and thus alter reabsorption vs. excretion (a practical pharmacokinetic tool).

• Practical application: What fraction of a drug is protonated vs unprotonated at a given pH is critical for predicting absorption and distribution. Small pH changes can shift the balance dramatically because the Henderson–Hasselbalch ratio changes by orders of magnitude with each unit of pH.

• Stepwise approach taught (the instructor’s method):
  1) Identify the drug’s class (weak acid or weak base) and its pKa. Decide which species you care about for crossing membranes (protonated for acids vs. protonated for bases).
  2) Use the Henderson–Hasselbalch form to compute the ratio of protonated to unprotonated at the relevant pH.
  3) Convert the ratio to an understanding of what fraction is charged vs uncharged, and infer membrane-crossing capability.
  4) Apply this to the specific compartment (gut, blood, urine, tissue) to predict absorption, distribution, excretion, and potential for ion trapping.

• Worked example (acid example – aspirin as a weak acid):

  • Assume aspirin has pKa ≈ 3.5.
  • Stomach pH ~ 1.5. Compute ratio:
    \frac{[\text{protonated}]}{[\text{unprotonated}]} = 10^{3.5 - 1.5} = 10^2 = 100:1.
    Interpretation: In the stomach, about 100 parts protonated (neutral) for every 1 part unprotonated (charged). Neutral form crosses membranes easily; absorption is favorable.
  • Small intestine pH ~ 7.5. Compute ratio:
    \frac{[\text{protonated}]}{[\text{unprotonated}]} = 10^{3.5 - 7.5} = 10^{-4} = 1:10{,}000.
    Interpretation: In the small intestine, the vast majority is unprotonated (charged) and poorly crosses membranes; absorption would be limited from a purely ionization standpoint in that local pH.
  • Net takeaway for acids: Absorption is highly pH-dependent; stomach conditions can favor absorption for weak acids like aspirin, while intestinal pH can impede it unless compensating factors (e.g., formulation, local microenvironments) are present.
  • If the drug were a weak base instead of an acid, the roles would reverse with protonated (charged) forms affecting permeability differently.

• Membrane crossing and lipophilicity:

  • The lipid membrane is hydrophobic; charged (ionized) forms are hydrophilic and cross poorly.
  • For acids, the neutral, protonated form crosses; for bases, the neutral uncharged form crosses best (depending on which species is neutral).
  • The professor emphasizes using protonated/unprotonated terminology consistently to avoid mix-ups about which form crosses at a given pH.

• Hydrophobicity and the oil–water partition coefficient (logP):

  • Increasing hydrophobicity (higher logP) generally enhances membrane permeability and gut absorption.
  • Example trend across barbiturate family: barbitone, secobarbital, thiopental – progressively longer hydrocarbon chains increase lipophilicity and the oil–water partition coefficient (O/W) by roughly two orders of magnitude or more (e.g., from about 50 to several hundred).
  • Conceptual experiment: If you shake a two-phase system (organic solvent vs. water), a more hydrophobic compound partitions more into the oil phase; greater hydrophobicity correlates with better membrane crossing.
  • Therefore, when predicting absorption, you consider both pKa/pH (ionization) and hydrophobicity (membrane permeability) together.

• Drug disposition in the body: compartments and the “highway” concept

  • Pharmacokinetic models often collapse the body into discrete fluid compartments connected by flux (drug movement).
  • The bloodstream is the central hub, because all routes of entry/exit eventually involve the blood as a transit path.
  • Schematic idea: Gut → blood → tissues → back to blood → excretion. The blood is the middle compartment through which most distribution passes.
  • Intravenous (IV) administration puts the drug directly into the blood, giving the most consistent dosing and pharmacokinetics.
  • Oral administration is the most patient-friendly but the most challenging pharmacokinetically due to absorption, first-pass metabolism, and variability.
  • Intramuscular and other routes exist; some routes involve portals (portal circulation) that deliver absorbed drug to the liver first.

• First-pass metabolism and the portal system:

  • If a drug is absorbed from the GI tract and enters the portal circulation, it goes to the liver before reaching systemic circulation.
  • The liver can metabolize or degrade a significant fraction of the drug before it ever reaches the bloodstream (the “first-pass effect”).
  • As a result, some oral drugs are dramatically reduced in bioavailability due to hepatic metabolism.
  • Direct intravascular routes (e.g., IV) bypass the portal liver first-pass effect, avoiding this major loss.
  • Enterohepatic cycling: Some drugs or their metabolites can be excreted into the bile, re-enter the gut, and be reabsorbed, prolonging exposure and half-life.

• Clinical manipulation of pH to influence pharmacokinetics (buffers and ion trapping):

  • Clinicians can adjust gastric juice pH (range ~1–3) and urinary pH (range ~4–8) with buffers to influence drug disposition.
  • Goals include extending a drug’s half-life by reducing renal excretion (keep drug charged so it is not reabsorbed) or accelerating clearance by increasing ion trapping in the nephron.
  • In overdose or toxicity scenarios, intentionally acidifying or alkalinizing urine can trap certain drugs in the nephron and promote excretion.
  • Important safety note: Blood pH is tightly regulated; altering blood pH (systemically) is dangerous and not clinically acceptable. Urine pH is modifiable within reasonable safety margins to affect excretion.

• Practical considerations and clinical strategy:

  • When evaluating a lead compound in drug development, a pharmacokinetic profile includes absorption, distribution, metabolism, and excretion characteristics, often summarized in compartment models.
  • Route of administration affects feasibility, cost, and patient compliance (IV is precise but inconvenient and expensive; oral is preferred but variable).
  • Early decision-making about pKa, hydrophobicity (logP/logD), and potential for first-pass metabolism guides lead optimization and selection.
  • In medicinal chemistry, modest structural changes (e.g., longer hydrocarbon chains) can shift lipophilicity and dramatically change gut absorption and tissue distribution.
  • Real-world example: Barbiturates show increasing lipophilicity with longer hydrocarbon chains, boosting oral absorption and CNS penetration, but also increasing duration of effect and potential toxicity.

• Summary of the test-oriented concepts you should be able to apply:

  • Determine the fraction protonated vs unprotonated at a given pH using \log \left(\frac{[\text{protonated}]}{[\text{unprotonated}]}\right) = \mathrm{p}K_a - \mathrm{pH} and interpret whether the drug will cross membranes in that compartment.
  • Assess whether a drug will be absorbed from the gut and reach systemic circulation based on its ionization state at the GI pH and its lipophilicity.
  • Predict whether a drug will be trapped in a compartment due to ion trapping, and how urine pH manipulation could alter renal clearance.
  • Recognize that absorption and distribution are pH-dependent, while blood pH is tightly regulated and cannot be purposefully altered; urine and gastric juice pH can be modified within safe limits for therapeutic or detoxification purposes.
  • Understand that first-pass metabolism in the liver can dramatically reduce oral bioavailability, and that alternate routes or formulations may circumvent this (e.g., IV, sublingual, etc.).

• Quick takeaways:

  • The protonation state of a drug in a given compartment dictates its membrane permeability and hence its absorption and distribution.
  • The Henderson–Hasselbalch equation is the essential tool for predicting charge state across pH changes.
  • Ion trapping and urine pH manipulation are practical tools in clinical pharmacology for modifying drug clearance.
  • Hydrophobicity (logP) and pKa together shape a drug’s absorption profile; increasing hydrophobicity generally increases gut absorption but can also affect distribution and clearance.

• Final reminder from the lecture:

  • When solving test questions, focus on the ratio of protonated to unprotonated species to determine membrane crossing and distribution (not just the math in isolation). The physical interpretation—will the drug cross the membrane or be trapped?—is what ultimately determines absorption, distribution, and excretion outcomes.